• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Pretreatment Immune Status, Predicts Response to Definite Chemo Radiotherapy in Advanced Stages of Cervical Cancer Patients.治疗前免疫状态可预测晚期宫颈癌患者对确定性放化疗的反应。
J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):319-325. doi: 10.1007/s13224-022-01624-z. Epub 2022 Feb 24.
2
An Altered Ratio of CD4+ And CD8+ T Lymphocytes in Cervical Cancer Tissues and Peripheral Blood – A Prognostic Clue?宫颈癌组织和外周血中CD4+和CD8+ T淋巴细胞比例的改变——一个预后线索？
Asian Pac J Cancer Prev. 2018 Feb 26;19(2):471-478. doi: 10.22034/APJCP.2018.19.2.471.
3
B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.B7-H4过表达会损害人宫颈癌中T细胞的免疫反应。
Hum Immunol. 2014 Dec;75(12):1203-9. doi: 10.1016/j.humimm.2014.10.002. Epub 2014 Oct 13.
4
Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study.CD4/CD8淋巴细胞比值升高预示胃癌新辅助治疗反应良好：一项前瞻性初步研究。
World J Gastrointest Oncol. 2023 Feb 15;15(2):303-317. doi: 10.4251/wjgo.v15.i2.303.
5
A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix.肿瘤浸润淋巴细胞的 CD4/CD8 比值倒置和 CD4(+)FOXP3(+)调节性 T 细胞的高比例与宫颈癌的临床结局显著相关。
Cell Mol Immunol. 2011 Jan;8(1):59-66. doi: 10.1038/cmi.2010.56. Epub 2010 Nov 22.
6
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.宫颈癌放化疗的免疫影响及免疫细胞浸润如何导致个体化治疗。
Int J Cancer. 2020 Jul 15;147(2):554-564. doi: 10.1002/ijc.32893. Epub 2020 Feb 26.
7
Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.尼妥珠单抗联合放化疗治疗中晚期宫颈癌患者前后外周血 T 淋巴细胞亚群的变化。
J Obstet Gynaecol. 2023 Dec;43(1):2179915. doi: 10.1080/01443615.2023.2179915.
8
Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.放射治疗期间输血对子宫颈癌患者免疫功能的影响：白细胞介素-10的作用
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1345-55. doi: 10.1016/s0360-3016(02)03757-4.
9
Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma.肿瘤浸润淋巴细胞的CD4/CD8比值倒置与人类宫颈癌的进展相关。
Cancer. 1999 Oct 15;86(8):1537-43. doi: 10.1002/(sici)1097-0142(19991015)86:8<1537::aid-cncr21>3.0.co;2-d.
10
[Lymphocyte activation markers in patients with ovarian cancer].[卵巢癌患者的淋巴细胞活化标志物]
Ginekol Pol. 2012 Oct;83(10):737-43.

引用本文的文献

1
Immune Profile of Blood, Tissue and Peritoneal Fluid: A Comparative Study in High Grade Serous Epithelial Ovarian Cancer Patients at Interval Debulking Surgery.血液、组织和腹腔积液的免疫谱：晚期减瘤手术的高级别浆液性上皮性卵巢癌患者的比较研究
Vaccines (Basel). 2022 Dec 12;10(12):2121. doi: 10.3390/vaccines10122121.

本文引用的文献

1
Local Destruction of Tumors and Systemic Immune Effects.肿瘤的局部破坏与全身免疫效应
Front Oncol. 2021 Jul 8;11:708810. doi: 10.3389/fonc.2021.708810. eCollection 2021.
2
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.通过 MHC I 类抗原呈递丧失实现癌症免疫逃逸。
Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021.
3
Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.肿瘤微环境中的调节性 T 细胞：新机制、潜在治疗策略和未来前景。
Mol Cancer. 2020 Jul 17;19(1):116. doi: 10.1186/s12943-020-01234-1.
4
A guide to cancer immunotherapy: from T cell basic science to clinical practice.癌症免疫疗法指南：从 T 细胞基础科学到临床实践。
Nat Rev Immunol. 2020 Nov;20(11):651-668. doi: 10.1038/s41577-020-0306-5. Epub 2020 May 20.
5
Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients.宫颈癌患者外周血和肿瘤组织淋巴细胞亚群的临床意义。
BMC Cancer. 2020 Mar 4;20(1):173. doi: 10.1186/s12885-020-6633-x.
6
T Cell Dysfunction and Exhaustion in Cancer.癌症中的T细胞功能障碍与耗竭
Front Cell Dev Biol. 2020 Feb 11;8:17. doi: 10.3389/fcell.2020.00017. eCollection 2020.
7
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.HPV 疫苗接种和宫颈筛查对宫颈癌消除的影响：78 个低收入和中低收入国家的比较建模分析。
Lancet. 2020 Feb 22;395(10224):575-590. doi: 10.1016/S0140-6736(20)30068-4. Epub 2020 Jan 30.
8
Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives.人乳头瘤病毒感染与宫颈癌：流行病学、筛查及疫苗接种——当前观点综述
J Oncol. 2019 Oct 10;2019:3257939. doi: 10.1155/2019/3257939. eCollection 2019.
9
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.细胞毒化疗作为一种免疫刺激剂：从分子角度看待癌症的免疫升温。
Front Immunol. 2019 Jul 17;10:1654. doi: 10.3389/fimmu.2019.01654. eCollection 2019.
10
Targeting immune cells for cancer therapy.针对免疫细胞的癌症疗法。
Redox Biol. 2019 Jul;25:101174. doi: 10.1016/j.redox.2019.101174. Epub 2019 Mar 20.

治疗前免疫状态可预测晚期宫颈癌患者对确定性放化疗的反应。

Pretreatment Immune Status, Predicts Response to Definite Chemo Radiotherapy in Advanced Stages of Cervical Cancer Patients.

作者信息

Garg Swati, Shekhawat Usha, Vohra Rajaat, Gupta Reshu

机构信息

Department of Obstetrics & Gynaecology, Mahatma Gandhi Medical College & Hospital, Jaipur, India.

Department of Community Medicine, Mahatma Gandhi Medical College & Hospital, Jaipur, India.

出版信息

J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):319-325. doi: 10.1007/s13224-022-01624-z. Epub 2022 Feb 24.

DOI:10.1007/s13224-022-01624-z
PMID:35928063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9343502/
Abstract

OBJECTIVE

To evaluate the prognostic role of pretreatment CD4 + , CD8 + T lymphocytes in predicting response to definite chemo radiotherapy in advanced cervical cancer. Design: A hospital-based prospective one-year follow-up study.

METHOD

This observational study was conducted on 74 patients with advanced cervical cancer. Pretreatment CD4 + and CD8 + levels in cervical cancer tissue and peripheral blood was noted and quantitatively assessed in patients with complete remission or persistent disease after one year of follow-up.

RESULTS

There was a statistically significant association of tumour volume with the remission or persistence of disease. In peripheral blood, mean CD4 + score and CD4 + /CD8 + ratio were significantly higher while mean CD8 + score is significantly lower in patients with remission. Similar results were seen in tumour tissue as well. On Receiver Operating Curve analysis, the cut-off value of CD4 + , CD8 + and CD4 + /CD8 + ratio in predicting remission or persistent disease in peripheral blood was 20.09, 18.51 and 0.41 while in tumor tissue was 19.71, 20.99 and 0.20, respectively.

CONCLUSION

The patients with tumor volume < 100 cm 2 have much higher chances of remission. The patients with higher CD4 + and CD4 + / CD8 + ratio, both in peripheral blood as well as tumor tissue, have higher chances of remission. The cut-off value of CD4 + , CD8 + and CD4 + /CD8 + ratio in predicting remission or persistent disease in peripheral blood was 20.09, 18.51 and 0.41 while in tumor tissue was 19.71, 20.99 and 0.20, respectively.

摘要

目的

评估治疗前CD4 +、CD8 + T淋巴细胞在预测晚期宫颈癌对确定性放化疗反应中的预后作用。设计：一项基于医院的前瞻性一年随访研究。

方法

对74例晚期宫颈癌患者进行了这项观察性研究。记录治疗前宫颈癌组织和外周血中CD4 +和CD8 +水平，并在随访一年后对完全缓解或疾病持续的患者进行定量评估。

结果

肿瘤体积与疾病缓解或持续存在之间存在统计学上的显著关联。在外周血中，缓解患者的平均CD4 +评分和CD4 + / CD8 +比值显著更高，而平均CD8 +评分显著更低。肿瘤组织中也观察到了类似结果。在受试者工作特征曲线分析中，外周血中CD4 +、CD8 +和CD4 + / CD8 +比值预测缓解或疾病持续的临界值分别为20.09、18.51和0.41，而在肿瘤组织中分别为19.71、20.99和0.20。

结论

肿瘤体积＜100 cm²的患者缓解机会更高。外周血和肿瘤组织中CD4 +和CD4 + / CD8 +比值较高的患者缓解机会更高。外周血中CD4 +、CD8 +和CD4 + / CD8 +比值预测缓解或疾病持续的临界值分别为20.09、18.51和0.41，而在肿瘤组织中分别为19.71、20.99和0.20。